G-protein-coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives

Publication date: April 2018 Source:Best Practice & Research Clinical Endocrinology & Metabolism, Volume 32, Issue 2 Author(s): Guido Sebastiani, Elena Ceccarelli, Maria Grazia Castagna, Francesco Dotta G-protein coupled receptors (GPCRs) represent the largest receptor family in the genome and are of great interest for the design of novel drugs in a wide variety of diseases including neurologic disorders, obesity and Type 2 diabetes mellitus. The latter is a chronic disease characterized by insulin resistance and impaired insulin secretion, affecting >400 million patients worldwide. Here we provide an overview on: a) The molecular basis of GPCR signalling and of its involvement in the regulation of insulin secretion and of glucose homeostasis; b) the role of GPCRs in type 2 diabetes pathophysiology and as therapeutic targets of current and future glucose-lowering drugs.
Source: Best Practice and Research Clinical Endocrinology and Metabolism - Category: Endocrinology Source Type: research